<DOC>
	<DOCNO>NCT00309387</DOCNO>
	<brief_summary>The Collaborative Italian-American Clinical Trial Nutritional Supplements Age-related Cataract ( CTNS ) 13-year study design primarily evaluate safety efficacy vitamin-mineral supplement ( Centrum ) contain recommend daily-allowance dosage ( RDA ) prevent age-related cataract delay progression participant early cataract baseline .</brief_summary>
	<brief_title>Collaborative Italian-American Clinical Trial Nutritional Supplements Age-related Cataract ( CTNS )</brief_title>
	<detailed_description>Despite dramatic increase rate cataract surgery last decade , age-related cataract still responsible 50 % case severe visual impairment develop country , high grow health care cost western country . CTNS design complement U.S. Age-Related Eye Disease Study ( AREDS ) evaluate much broad spectrum nutrient RDA dosage . Whereas 60 % AREDS control group take RDA dose multivitamin supplement , none participant CTNS take type nutritional supplement least one year qualification visit . Therefore , CTNS able evaluate effect RDA dose versus supplementation . CTNS AREDS use similar procedure , include grade presence severity lens change . CTNS randomize , parallel group , placebo control , double blind , single center , intervention trial . Primary Outcomes : photographic evaluation prespecified increase baseline nuclear , cortical , posterior subcapsular cataract ( PSC ) opacity grade cataract surgery . Secondary Outcomes : increase type-specific opacity grade , cataract surgery , visual acuity loss baseline &gt; = 15 letter . Patients follow maximum 10 year .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<criteria>Clinical photographic diagnosis early agerelated cataract Participants early cataract must least one eligible eye VA score 20/32 good Participants cataract must VA score 20/32 good eye . Advanced cataract Bilateral aphakia pseudophakia Any ocular disease condition might complicate future evaluation cataract Regular use nutritional supplement Failure take least 75 % runin medication Cancer evidence recurrence past 5 year Major cerebral cardiovascular event past 12 month Current participation clinical trial Any condition likely prevent adherence CTNS followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Cataract</keyword>
	<keyword>Nutritional supplement</keyword>
</DOC>